🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06998082
Starting soon Observational

AI-Driven Early Warning System for Perioperative Risks in Acute Hemorrhagic Stroke

NCT06998082 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Tiantan Hospital
Phase
Observational
Started
2025-07-06
Last updated
2025-05-31

Condition(s) studied

Acute Hemorrhagic Stroke

Study summary

Acute hemorrhagic cerebrovascular disease is a life-threatening condition characterized by sudden onset, rapid progression, multiple complications, poor prognosis, and high mortality. It presents a significant public health burden. During surgical interventions, precise risk stratification and effective perioperative management are crucial to mitigating intraoperative and postoperative complications, optimizing disease diagnosis, guiding severity assessment, and refining anesthesia strategies. Continuous real-time evaluation and dynamic perioperative adjustments are essential to minimize the influence of institutional variability and individual clinician-dependent decision-making. By harnessing big data-driven, evidence-based medical approaches, clinicians can enhance diagnostic accuracy and therapeutic precision, addressing a critical challenge in reducing morbidity and mortality in this patient population.

This study aims to develop a comprehensive multimodal perioperative database and leverage large language models (LLMs) for the efficient extraction of structured demographic and clinical data throughout the perioperative course. By integrating real-time hemodynamic monitoring parameters, the investigators seek to elucidate the relationship between perioperative hemodynamic patterns and the incidence of postoperative complications affecting major organ systems, including the brain, heart, kidneys, and lungs. The ultimate goal is to construct a multimodal fusion early-warning model capable of real-time, simultaneous prediction of multiple perioperative complications. This AI-driven platform will function as a risk stratification and alert system for organ-specific perioperative complications in patients with acute hemorrhagic cerebrovascular disease. By providing evidence-based insights for optimized perioperative management-encompassing early warning mechanisms, diagnostic support, and individualized therapeutic strategies-the system aims to improve clinical outcomes, reduce perioperative morbidity, and lower overall mortality.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Patients aged 18 to 80 years. * Diagnosis confirmed by preoperative imaging (CT or MRI) of one of the following conditions: * Intracranial aneurysm * Arteriovenous malformation (AVM) * Hemorrhagic moyamoya disease * Cavernous malformation * Spontaneous intracerebral hemorrhage * Undergoing surgery within seven days of symptom onset. Exclusion Criteria: * Patients who decline to provide informed consent. * Patients enrolled in conflicting clinical studies.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Beijing Tiantan Hospital Beijing Beijing Municipality

More Beijing Tiantan Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06998082 on ClinicalTrials.gov ↗ ← All trials in China